News
FDA approves drug with new mechanism of action for treatment of schizophrenia
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults....
Lilly’s Kisunla approved in Japan for the treatment of early symptomatic Alzheimer’s disease
The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly...
AskBio and Belief BioMed to explore potential of new gene therapies
Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer, has announced a new strategic collaboration with...
